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Hereditary cystatin C amyloid angiopathy is a dominantly inherited disease caused by a
leucine to glutamine variant of human cystatin C (hCC). L68Q-hCC forms amyloid deposits in
brain arteries associated with micro-infarcts, leading ultimately to paralysis, dementia and
death in young adults. To evaluate the ability of molecules to interfere with aggregation of
hCC while informing about cellular toxicity, we generated cells that produce and secrete WT
and L68Q-hCC and have detected high-molecular weight complexes formed from the mutant
protein. Incubations of either lysate or supernatant containing L68Q-hCC with reducing
agents glutathione or N-acetyl-cysteine (NAC) breaks oligomers into monomers. Six L68Q-
hCC carriers taking NAC had skin biopsies obtained to determine if hCC deposits were
reduced following NAC treatment. Remarkably, ~50–90% reduction of L68Q-hCC staining
was observed in five of the treated carriers suggesting that L68Q-hCC is a clinical target for
reducing agents.
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Hereditary cystatin C amyloid angiopathy (HCCAA) is adominantly inherited disease caused by a leucine 68 toglutamine variant of human cystatin C (hCC, L68Q-
hCC)1. HCCAA is classified as a cerebral amyloid angiopathy
(CAA), a group of diseases in which amyloid deposits form on the
walls of blood vessels in the central nervous system (CNS).
Although HCCAA is rightly classified as a CAA disorder due to
its strong cerebral presentation, hCC deposition is systemic and
also found in other internal organs. Most carriers of the mutation
suffer microinfarcts and brain hemorrhages in their twenties,
leading to paralysis, dementia, and death in young adults, with an
average life expectancy of 30 years2–6. Postmortem studies in
humans show hCC deposits in all brain areas, most prominently
in arteries and arterioles.
Human cystatin C, a cysteine protease inhibitor that belongs to
the cystatin superfamily, is a secretory type 2 cystatin, expressed
in all nucleated human cells and found in all tissues and body
fluids and at particularly high concentrations in cerebrospinal
fluid2,7–9. hCC inhibits cysteine proteases like papain and legu-
main by its interaction through multiple binding motifs resulting
from the characteristic hCC fold9–11. Its normal conformation is
composed of a polypeptide that folds into a five-stranded β-sheet,
which partially wraps around a central α-helix. The N-terminal
segment and two hairpin loops build the edge of the protein,
which binds into the active site of cysteine proteases and blocks
their proteolytic activity12–14. Mutation of leucine 68 to glutamic
acid destabilizes the packing between the beta sheets and the
alpha helix, allowing the molecule to open. Two such open hCC
molecules can interact with each other, with the helix of each
molecule interacting with the beta sheet of the other; the resulting
dimer is said to be the product of domain swapping15–17. Addi-
tionally, through a process called propagated domain swapping,
long chains of molecules can be built, in which the free domain of
each molecule interacts with a new hCC monomer18. The
aggregation of proteins leads to the formation of highly ordered
pathogenic fibrillar aggregates, called amyloid fibrils19,20, which
are implicated not only in HCCAA but also in a wide range of
neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
Creutzfeldt–Jacob’s, and Huntington’s disease20.
The degree of amyloid maturation observed in cystatin C
deposits has been shown to vary between tissues (i.e., less promi-
nent maturation in skin than in brain)21. Although deposits in the
skin are not composed of amyloid fibers, quantitative studies on
hCC deposition within the skin of mutant carriers showed that
symptomatic carriers had significantly higher levels of hCC
immunoreactivity in their skin than asymptomatic carriers. The fact
that the quantity of hCC deposition in skin was associated with the
progression of the disease in the CNS shows that skin biopsies are
useful in assessing disease progression and could, therefore, be of
use in the evaluation of therapeutic interventions22.
Protein oligomers of different pathogenic amyloidogenic pro-
teins precede the fibril formation stage in HCCAA and other
diseases, although for HCCAA, it is unclear if such oligomers lead
directly to pathogenic fibrils or if assembly of fibrils occurs most
rapidly from monomers23. Drugs reducing aggregation of
amyloid-producing proteins have the potential to reduce the
formation of toxic oligomers known to occur in several types of
amyloidosis24,25. Previous investigations have suggested that
preventing domain swapping of hCC might be used for treatment
of HCCAA24; Nilsson et al.26 developed variants of WT hCC and
L68Q-hCC with intra-chain-stabilizing disulfide bonds prevent-
ing domain swapping; stabilized molecules could not form
dimers. These results suggest that the knowledge of the molecular
mechanism causing the transition of physiologically normal and
soluble proteins to toxic oligomers and insoluble fibrils is essential
for the development of treatment strategies.
Östner et al.24 have previously attempted to prevent poly-
merization of hCC monomers, or disrupt or remove multimeric
species, through various approaches. As mentioned, use of sta-
bilized hCC monomers demonstrated that preventing domain
swapping prevents aggregations. Antibodies can be raised speci-
fically against the domain swapped, dimeric form of hCC; those
antibodies were able to specifically remove dimers of hCC, and
not monomers, from patient plasma using size-exclusion
chromatography27. A high-throughput screen of compounds
has been pursued using the US Drug Collection (composed of
1040 FDA-approved compounds, http://www.msdiscovery.com/
usdrug.html) in an effort to find molecules that prevent
dimerization24. Although promising, this approach required large
amounts of purified hCC protein produced in bacteria, and the
compounds identified as inhibiting dimer formation were for the
most part used at concentrations too high to be considered
therapeutic in an organism.
To create a system in which to test the ability of a compound to
impact hCC multimerization while gaining some insight into its
toxicity, we created cell lines that express high amounts of either
wild type or mutant hCC. This study describes our character-
ization of the cell lines and the monomeric and multimeric hCC
that they create and attempts to nontoxically interfere with
aggregation of the mutant protein. We also present the effects of
NAC taken as a drug prescribed for mucolytic therapy or taken
voluntarily as a supplement on hCC deposition in skin biopsies of
human subjects with HCCAA.
Results
Incubation with glutathione impairs hCC di-/oligomerization
in cellular extracts and supernatants. In our efforts to create a
cell model and detection system for examining the effects of
potential therapeutic agents on aggregation of L68Q-hCC, we
created stable transfectants of HEK293T cells overexpressing and
secreting either WT- or L68Q-hCC. We observed profound lad-
dering on Western blots in lysates and the existence of only high-
molecular-weight species (HMW) in supernatants of cells
expressing the mutant (Supplementary Fig. 1), but only if the
samples were run under nonreducing conditions. The laddering
in lysates corresponds to the predicted molecular weights of
monomeric hCC and discrete multimers of hCC (dimer, trimer,
and tetramer), which we refer to as smaller species (dimer, trimer,
and tetramer) and low-molecular-weight (LMW) complexes.
Conversely, wild-type protein expressed and secreted pre-
dominantly as a monomer. Treatment of mutant lysates or
supernatants with the reducing agent DTT (dithiothreitol) col-
lapsed practically all the protein to monomeric size, suggesting
that disulfide bonds, either intramolecular or intermolecular, are
required for observation of multimers and larger species on
denaturing sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE).
DTT is not appropriate for therapeutic use, but multiple
naturally occurring reducing agents exit. To examine the efficacy
of such a compound, supernatants and cellular extracts of WT or
L68Q-hCC-expressing cells were treated with different concen-
trations of reduced glutathione (GSH) at 37 °C for 15 min. As
Fig. 1 shows, treatments with 3 or 10 mM of GSH severely
reduced the amount of dimer and/or HMW oligomer observed in
both the secreted and the intracellular fraction of L68Q variant.
Quantitation showed that 3 mM of GSH displayed an ≈90%
reduction of the HMW in the secreted fraction and an ≈50%
inhibition in the intracellular fraction (lysates) of the L68Q-hCC
variant (Fig. 1 and Supplementary Fig. 2). Unexpectedly, we
observed an overall increase in the amount of protein observed
with increasing amounts of GSH. For the mutant protein, this
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apparent increase may be explained by the destruction of large
protein complexes resulting in increasing amounts of monomer.
However, this explanation would not be expected to apply to the
wild type. A second potential explanation is that the epitope
recognized by the anti-cystatin C antibody used for blotting may
be partially masked under nonreducing conditions. Treatment
with reducing agents under such circumstances would result in
increased detection by Western blot. In addition, as seen in
Supplementary Fig. 1B, the wild-type protein can be observed in
higher-molecular-weight species in longer exposures; those larger
species would also serve as sources of monomer upon treatment
with reducing agents.
Incubation with NAC or gluthathione impairs dimerization of
secreted L68Q-hCC. The oxidized/reduced glutathione pair is
critical to fight against oxidative stress, and, as shown in Fig. 2, it
can effectively disrupt the dimers and HMW oligomers of hCC.
Accordingly, we analyzed whether another reducing agent, the
commonly used dietary supplement n-acetyl cysteine (NAC),
would affect the oligomerization/dimerization of secreted hCC.
Supernatants were treated with different concentrations of GSH
and NAC at 37 °C for 60 min. As Fig. 2 shows, treatments with 3
or 10 mM of either reagent reduced the oligomerization/dimer-
ization levels of secreted L68Q-hCC in vitro. Quantitation
showed almost complete ablation of HMW with 3 mM con-
centrations of either GSH or NAC (Fig. 2 and Supplementary
Fig. 3). This result demonstrates that GSH or NAC are able to
decrease the oligomerization levels of the pathogenic version of
L68Q-hCC and can be potentially used as treatment of HCCAA
patients. Supplementary Figure 3 contains the replicate experi-
ments used for quantitation, and shows the large difference in
secretion between wild-type and mutant proteins.
Detection of L68Q-hCC complexes by sucrose gradient cen-
trifugation. The SDS-PAGE-based method for detecting oligo-
mers of L68Q-hCC denatures proteins as part of its execution,
and as such, the method itself may contribute to breaking HMW
and LMW species down to monomers. As a denaturation-
independent method of detecting the effects of reducing agents on
L68Q-hCC complexes, sucrose gradient-density ultracentrifuga-
tion was performed. Lysates from L68Q-hCC cells were treated
with NAC or the strong reducing agent β-mercaptoenthanol and
loaded on top of sucrose gradients. Following ultracentrifugation,
fractions were collected from the gradient and proteins were
precipitated. The presence of hCC in each fraction was detected
by Western blot (Fig. 3). L68Q-hCC was present in all fractions of
the gradient, with the majority of the protein present in the
middle- and lower-density fractions. However, detectable
amounts of L68Q-hCC were also present in the densest fractions
of the gradient. Treatment with β-mercaptoenthanol resulted in a
loss of L68Q-hCC from the two densest fractions of the gradient,
suggesting the loss of the largest complexes. Treatment with NAC
resulted in loss of mutant protein from the densest fraction, and a
reduction of protein present in the second densest fraction. These
results provide evidence, from an independent biochemical
method, that NAC is capable of breaking HMW complexes of
L68Q-hCC into smaller or less-dense species.
Presence of GSH or NAC reduces oligomerization of secreted
L68Q-hCC at 24, 48, and 72 h. To investigate whether NAC or
GSH reduces the oligomerization of secreted L68Q-hCC in a
cellular system, we treated cells expressing WT or L68Q-hCC
with both agents. Cells were seeded in plates and allowed to
secrete hCC for 48 h, at which point increasing concentrations of
GSH or NAC were added to the cultures. Cells were cultured for
72 h in the presence of reducing agents, with samples of the
supernatants being removed after 24, 48, and 72 h. Oligomer-
ization status of hCC was determined by Western blot at each
time point. No gross differences in morphology were observed for
the duration of the experiment in the presence of all concentra-
tions (up to 10 mM) of both reducing agents. As shown in Fig. 4
(and Supplementary Fig. 4), treatment of cells with 10 mM GSH
or NAC completely abolished the presence of HMW and LMW at
the 24 and 48-h time points, and appreciable but incomplete
reduction of HMW and LMW persisted at 72 h. Treatments with
lower doses of NAC or GSH were only incompletely effective at
24 and 48 h and no significant effect was detected after 72 h
(Fig. 4).
Incubation with NAC derivatives impairs dimerization of
secreted L68Q-hCC. NAC should have a variety of protective
antioxidant effects; however, some clinical trials failed to confirm
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Fig. 1 Incubation with glutathione impairs cystatin C di-/oligomerization
in cellular extracts and supernatants. Supernatants and cellular extracts
from hCC WT- (a) or L68Q-expressing (b) cells were incubated in the
presence of glutathione (GSH) at the indicated concentrations for 1 h at 37
°C. Samples were mixed with 2% SDS without reducing agents prior to
electrophoresis, and protein levels were detected by Western blot for
cystatin C, and amounts of monomeric hCC (Mono) or high-molecular-
weight hCC species (HMW) were quantitated (N= 3 independent
experiments; one-tailed student t test; indicated p values were less than
0.05, without correction for multiple testing, with respect to untreated). In
blots and graphs, bars are means, error bars represent standard deviation.
Gel images for replicate experiments are shown in Supplementary Fig. 2.
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such beneficial effects. A possible explanation for this absence of
beneficial effects could be its low oral bioavailability or its complex
intestinal absorption. Additionally, several discrepancies have been
reported in the literature about the ability of the NAC to cross
blood–brain barrier (BBB). These problems have stimulated the
search for alternative pharmacologically favorable cysteine pro-
drugs like NAC amide (NACA) or NAC-Methyl esther (NAC-Me).
These newly prepared derivatives of NAC include groups to facil-
itate membrane diffusion and have been shown to cross the BBB
and to protect from oxidative injury in animal models and in cul-
tured cells28,29. In order to investigate if these agents display similar
effects to that of NAC, we analyzed whether other reducing agents
(like NACA and NAC-Me) would affect the oligomerization/
dimerization of secreted hCC. Supernatants were treated with dif-
ferent concentrations of NAC, NACA, or NAC-Me at 37 °C for 60
min. As Fig. 5a shows, treatments with 3 or 10mM of NAC or 1, 3,
or 10mM of NACA or NAC-Me reduced the oligomerization/
dimerization levels of secreted L68Q-hCC in vitro. Quantitation
showed almost complete ablation of HMW with 3mM con-
centrations of NAC or concentration of 1mM of NACA or NAC-
Me. This result demonstrates that NAC or its derivatives (NACA
and NAC-Me) are able to decrease the oligomerization levels of the
pathogenic version of L68Q-hCC; indeed, NAC derivatives showed
a stronger activity (around 10 times stronger activity). We also
treated cells for 24 h with the NAC derivatives, as in Fig. 4. As
shown in Supplementary Fig. 6, the derivatives were more effective
than NAC in cell culture, and as with NAC, no gross differences in
morphology were observed for the duration of the experiment in
the presence of all concentrations (up to 10mM) of all reducing
agents. Supplementary Figure 5 contains the replicate experiments
used for quantitation, and shows the large difference in effect
between NAC and its derivatives.
Effects of NAC administration in HCCAA patients. The L68Q-
hCC mutation is a founder mutation in the Icelandic population
that occurred approximately 18 generations ago during the 16th
century4, with most mutation carriers suffering microinfarcts and
brain hemorrhages as young adults, ultimately leading to
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Fig. 2 Glutathione and N-acetylcysteine impairs oligomerization of secreted cystatin C L68Q. Supernatants were incubated in the presence of the
indicated concentrations of glutathione or NAC for 1 h at 37 °C. Samples were mixed with 2% SDS without reducing agents prior to electrophoresis, and
protein levels were detected by anti-cystatin C antibody and amounts of monomeric hCC (Mono) or high-molecular- weight hCC species (HMW) were
quantitated. No HMW fraction was detected in supernatants from HEK-293T cells stably expressing hCC WT (N= 3 independent experiments; one-tailed
student t test; indicated p values were less than 0.05, without correction for multiple testing, with respect to untreated). Bars are means, error bars
represent standard deviation. Gel images for replicate experiments are shown in Supplementary Fig. 3.
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described cellular work, it became evident that NAC could
potentially be useful to treat this devastating disease. The proband
in one of the HCCAA families in Iceland had sustained three
serious strokes over 9 months at the age of 22 and required an
intensive care unit stay due to paralysis and respiratory failure
complicated by recurrent atelectasis. Following the third stroke,
the proband was bound to a respirator and was suffering from
mucus plugging and atelectasis. Coincidentally to our findings in
the cell models, the proband was treated with the mucolytic agent
NAC and mucous plugging gradually resolved. As a result of the
effects of NAC in the described cell system, the proband was
maintained on the NAC therapy. A parent and a sibling of the
proband, both carriers of the mutation, also elected to begin
taking NAC as a food supplement in light of the effects of NAC
observed in the cell system (Fig. 6a). This was prior to subse-
quently enrolling in a clinical trial testing the efficacy of NAC in
patients with HCCAA, that launched in 2019. Three additional
extended family members and carriers of the mutation (Fig. 6b)
also decided to begin taking NAC as a food supplement, based on
information from the proband family, prior to enrolling into the
NAC clinical trial in 2019. All three individuals had a historical
skin biopsy at the time of their diagnosis and a follow-up skin
biopsy done 6–24 months after they began taking NAC as a food
supplement.
While the amount of mature amyloid fibrils differs between
tissues in HCCAA patients, it has been recently shown that the
amount of deposits in the skin correlates with the symptomatic or
asymptomatic status of patients, with higher deposition in skin
observed in symptomatic individuals22. While we cannot directly
monitor the impact of NAC on hCC deposition in the brain, we
chose to investigate the effect of NAC therapy on hCC deposition
in skin as a proxy for its activity in the brain. Skin biopsies from
subjects were obtained under a research protocol described in the
“Methods” section. For the first three patients, three biopsies were
taken from each individual (Fig. 6a). Biopsy #1 was a historical
biopsy performed at the time of diagnosis of the proband, over 5
years ago for research purposes; biopsy #2 was performed after
the proband was being treated with 400 mg of NAC 4× per day
for a total duration of 9 months, for the respiratory problems
resulting from mucus plugging as discussed above; this was just
prior to all three subjects starting a NAC dose of 600 mg 3×
per day and served as a baseline to assess for NAC biomarker
response in the parent and sibling. Biopsy #3 was performed
following 6 months of NAC treatment at 600 mg 3× per day and
was used to determine skin biomarker response to NAC therapy.
All biopsies were stained together and at the same time to limit
batch effects. On the three additional patients, 2 biopsies were
taken from each individual (Fig. 6b). Biopsy #1 was a historical
biopsy performed in 2017 (carrier 1), 2018 (carrier 2), and 2015
(carrier 3), for research purposes. Biopsy #2 was performed after
carrier 1 had been treated with 600mg of NAC 3× per day for
24 months, carrier 2 for 8 months, and carrier 3 for 9 months.
Figure 6 demonstrates the changes in staining over the course of
the observations. The cystatin C deposition was most evident in
the basement membrane between the epidermis and dermis (the
deposition has been shown to begin in this area in asymptomatic
carriers), but was also present in basement membranes around
dermal arteries, arterioles, veins, hair follicles, sebaceous glands,
fat/sweat glands, and arrector pili muscles. Overall, the drug
reduced the percentage of the dermis and epidermis showing hCC
staining. Whether decreased deposition in skin following treat-
ment correlates with decreased deposition in brain or other tissues
or organs will require more detailed and sophisticated investiga-
tion. In addition, deposition in the skin has been shown to not
consist of mature amyloid fibers, although amyloid-like threads
have been shown by electron microscopy analyses22,30. Whether
or not NAC treatment affects fully mature amyloid deposits found
in brain and other tissues remains to be investigated.
In the first patient set (Fig. 6a), the proband had very high
levels of hCC protein complex deposition in the first skin biopsy.
Subsequent biopsies reveal the proband had not progressed in
terms of deposition; rather, the deposition had decreased by about
40%, as measured by hCC immunoreactivity between skin
biopsies #1 and #2 during which the proband was on NAC
therapy 400 mg 3× per day to treat lung atelectasis. In contrast,
the sibling (who also carries the L68Q mutation and was not on
NAC between biopsies #1 and #2) showed significant progression
in immunoreactivity, reflective of an increase in hCC protein
complex deposition in the skin. The parent showed smaller
progression of deposition between biopsies #1 and #2. When skin
biopsy #3 was obtained 6 months later, the proband demon-
strated a visible reduction in the hCC deposition in biopsy #3 in
comparison with the original skin biopsy. In the second patient
set (Fig. 6b), carriers 1 and 2 showed a visible reduction in the
hCC deposition, while carrier 3 showed a slight progression. It
should be noted that carrier 3 (Fig. 6b, bottom panel) had first
biopsy done over 3 years before beginning NAC therapy,
suggesting that the intensity of staining in the skin may have
been higher at the time NAC therapy began and that a potential
response was masked by the time lag.
The reduction in hCC deposition in the proband from first
biopsy to third (approximately 15 months at two different doses)
was estimated at ~70% (Fig. 6a). The parent demonstrated an
~50% reduction in staining on biopsy #3 (Fig. 6a), and the sibling
~30% after 6 months of NAC. In the second cohort, carriers 1 and
2 showed a visible reduction in the hCC deposition with carrier 1
having near- complete clearance following 600 mg of NAC 3×
per day for 24 months. Carrier 3 showed an increase in staining;
as discussed, this analysis is complicated by the gap between the
baseline biopsy and initiation of therapy. In total, five of six
treated subjects showed a demonstrable reduction in hCC
staining in skin following NAC therapy. The pre- and post-
treatment stainings for all six subjects show statistically significant
reduction (one-tailed, paired student t test, p= 0.028, Fig. 6c).
Discussion
Identification of agents with the ability to reduce L68Q-hCC
dimerization and amyloid fibril formation is the key for the
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Fig. 3 N-acetylcysteine reduces L68Q-hCC density in sucrose-gradient
ultracentrifugation. L68Q-hCC cell lysates were treated with β-
mercaptoethanol (β-MetOH) or n-acetyl cysteine (NAC) for 1 h at 37 °C.
Lysates were layered on top of sucrose step gradients, ranging from 5%
sucrose at the top (fraction 1) to 30% at the bottom (fraction 9) in 5%
increments. Gradients were ultracentifuged in a swinging bucket rotor for
16 h at 4 °C and 246,000×g. Fractions were collected from gradients,
proteins were precipitated with tricholoroacetic acid, and precipitated
proteins were dissolved in PBS before analysis by SDS-PAGE under
reducing conditions. Gels were blotted for cystatin C. The image is
representative of three independent experiments and sucrose gradients.
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development of treatments for HCCAA. Here, we created cells
that produce and secrete detectable levels of hCC (WT or L68Q)
capable of oligomerizing under nonreducing conditions, and we
then show that short incubation with GSH, NAC, or NAC deri-
vatives breaks oligomers into monomers. We show that treatment
of cell cultures with either GSH or NAC reduces oligomerization
of the secreted hCC L68Q at 24, 48, and 72 h. In addition, we
have successfully tested NAC derivatives NAC-A or NAC-Me,
which are also able to reduce oligomerization of the secreted hCC
L68Q. Treatment with NAC in human patients not only prevents
ongoing deposition of cystatin C protein complex in the skin, but
also reduces prior deposits in a significant way. Statistically sig-
nificant reduction of staining in skin was seen in the six patients
treated. The small number of subjects in this study is a caveat, and
analysis of a larger number of subjects in the context of a clinical
trial would be required to confirm these results and assess efficacy
of the compounds. A NAC clinical trial was launched in 2019 and
the results are anticipated in Q2, 2021 (EudraCT#: 2017-004776-
56). Previous systems for the study of the dimerization of hCC
had been developed. Most of the in vitro work was performed
mainly with bacterially produced and purified WT hCC24.
Absence of tests of promising candidates on the L68Q variant
makes it difficult to translate the in vitro results obtained by
previous analysis into in vivo studies.
Previous cellular studies have made use of exogenously
expressed hCC, both wild type and mutant, in characterization of
intracellular trafficking, secretion, multimer formation, and pro-
tein stability. Merz et al.31 observed a large hCC-containing
complex of greater than 70 kDa in lysates of transfected Chinese
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Fig. 4 NAC impairs oligomerization of secreted hCC L68Q. 293T cells expressing WT or L68Q cystatin C were incubated with media containing the
indicated amount of either glutathione (GSH) or n-acetyl cysteine (NAC) for 24, 48, or 72 h. Small amounts of supernatant were removed from the cells
and analyzed by Western blot at the indicated times. On days 2 and 3, only the supernatants from cells expressing hCC L68Q variant were analyzed.
Samples were mixed with 2% SDS without reducing agents prior to electrophoresis, protein levels were detected by anti-cystatin C antibody, and amounts
of monomeric hCC (Mono) or high-molecular-weight hCC species (HMW) were quantitated (N= 4 independent transfections; one-tailed student t test;
indicated p values were less than 0.05, without correction for multiple testing, with respect to untreated). Bars are means, error bars represent standard
deviation. Experiments from which replicate measurements are derived are shown in Supplementary Fig. 4.
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previous work dealing with secreted protein have focused on
comparatively small protein species (below 50 kDa). To our
knowledge, this work is the first to describe the presence of L68Q-
specific high-molecular-weight species in supernatants of trans-
fected cells secreting hCC.
Exposure of L68Q-hCC expressing cells to GSH, NAC, or NAC
derivatives in culture led to reduced accumulation of high-
molecular-weight species in supernatants. Reducing agents might
only be effective on the extracellular pools of L68Q-hCC in vivo,
but this may be sufficient to be of therapeutic benefit. Patho-
genesis in HCCAA occurs as the result of accumulation of protein
extracellularly, particularly inside blood vessels, where the
aggregates would be accessible. In addition, NAC has been shown
to cross the BBB32,33, but with limited bioavailability in the brain.
It has been previously proposed that derivatives of NAC may
possess better properties in this regard28,29. We have tested two
NAC derivatives in our cell-based system, both of which appear
to have improved pharmacokinetic profiles28,29,34,35 and they
have shown even stronger effects than NAC, suggesting they may
be therapeutic options. More testing needs to be performed before
these derivative compounds can be administered to humans.
L68Q-hCC is highly amyloidogenic, and subjects carrying the
corresponding mutation suffer from severe cerebral amyloidosis,
leading to brain hemorrhage and death in early adult life26. The
age of onset of clinical symptoms has dropped dramatically over
the natural history of the disease, with a reduction in lifespan
from approximately 65 years of age in 1825 to the current day
average of 304. Lifestyle changes that occurred in the Icelandic
population along with the economic and industrial changes of the
19th century are postulated as environmental factors influencing
the onset of disease in HCCAA. Increased consumption of car-
bohydrates occurred over this period. Hyperglycemia has been
linked to oxidative stress in diabetes36,37, and it is possible that
increased carbohydrates in Icelandic diets in the 19th century
created enough oxidative stress in L68Q-hCC carriers to make
presentation of the disease more severe. This hypothesis is
compatible with our results; increased oxidative stress would
increase multimerization of L68Q-hCC, and dietary reducing
agents like NAC would reverse that effect and prevent deposition
of new aggregates. Therapeutic benefits would be derived mainly
from the lack of new occlusions causing new strokes.
Under normal conditions, GSH levels are regulated by the rates
of its synthesis and its export from cells. However, GSH levels are
also influenced by agents or conditions that alter the thiol redox
state (leading to the formation of glutathione S-conjugates or
complexes) or that disrupt the distribution of GSH among var-
ious intracellular organelles. In addition, GSH levels are affected
by nutritional status and hormonal/stress levels, exhibit devel-
opmental and diurnal variations, and are affected by certain
physiological states, including pregnancy and exercise38–45.
Physiological levels of GSH in blood should provide an appro-
priate antioxidant environment that avoids extracellular accu-
mulation of proteins. However, the presence of mutations like
L68Q-hCC or deficiencies in the levels of GSH, as a consequence
of nutritional status or age, could lead to the undesired accu-
mulation of misfolded proteins4. Treatments that lead to
increases in GSH may help combat oxidative stress-induced
damage, which the presented results suggest may include
HCCAA-associated amyloid deposition.
NAC is a synthetic N-acetyl derivative of the endogenous
amino acid L-cysteine, a precursor of the antioxidant glutathione.
Both GSH and NAC already have been approved for use in
humans and have been administered at high doses for long per-
iods without adverse side effects46,47. They work as a direct
reactive oxygen species scavenger and as a source of sulfhydryl
groups. NAC, in addition, also regenerates liver stores of GSH.
These effects confer to NAC the ability to reduce disulfide bonds
and are the reason why NAC is widely used to reduce viscosity
and elasticity of mucus. Our data show that treatment with strong
reducting agents (DTT) or antioxidants (GSH and NAC) abolishes
hCC oligomerization in our cell model system. This effect indi-
cates that disulfide bond formation is essential for the oligomer-
ization process. However, the precise mechanisms by which GSH
or NAC modulates hCC protein oligomerization remain elusive
and need to be fully explored. Disulfide bonds have not been
shown to be directly involved in the dimerization process26;
however, the presence of two disulfide bonds in human cystatin C
(as in all type 2 cystatins), and the preservation of them in the
dimeric structure indicates its key role in the protein structure26.
We postulate that the intramolecular disulfide bonds are essential
for the correct folding of the hCC monomer and for the exchange
of three-dimensional subdomains between the two subunits of the
dimer and their reduction abolishes the oligomerization. Alter-
natively, the L68Q proteins in our system may form inter-
molecular disulfide bonds that are not described in the existing
dimeric crystal structures. Further work will be required to char-
acterize the precise complexes that are being produced and created
in this system. Despite these limitations, this cell system led to
identification of a compound (NAC) that has effects on cystatin C
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Fig. 5 NAC derivatives impairs oligomerization of secreted hCC L68Q.
Supernatants were incubated in the presence of the indicated
concentrations of n-acetyl cysteine (NAC), NAC amide (NACA), or NAC-
Methyl esther (NAC-Me) for 1 h. Samples were mixed with 2% SDS
without reducing agents prior to electrophoresis, protein levels were
detected by anti-cystatin C antibody, and amounts of monomeric hCC
(Mono) or high-molecular-weight hCC species (HMW) were quantitated
(N= 5 independent experiments, 2 containing only NAC-A and 3
containing NAC-A and NAC-Me; one-tailed student t test; indicated p
values were less than 0.05, without correction for multiple testing, with
respect to untreated). Bars are means, error bars represent standard
deviation. Gel images for replicate experiments are shown in
Supplementary Fig. 5.
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We hypothesize that treatment with NAC will reduce oligo-
merization of secreted hCC, thus reducing amyloid formation in
the brain of patients with HCCAA, either directly or through the
induction of GSH. Treatment with GSH may be effective; how-
ever, its low bioavailability limits the interest of supplementation
as therapeutic option for the treatment of patients with HCCAA.
NAC appears to be a good candidate because of its role in
restoring GSH levels, antioxidant properties, and its ability to
break disulfide bonds48. In addition, NAC supplementation sig-
nificantly improved coronary and peripheral vasodilatation49.
Specific to brain disorders, NAC has been trialed with some
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suggest that it warrants further investigation for effectiveness in
HCCAA. It is worth noting that antioxidants in general, and in
some cases NAC specifically, have been clinically trialed in other
dementia-related settings with minimal or no significant effect51.
Endpoints like memory and comprehension may represent
damage to the brain that is irreversible, leading to disappointment
in previous trials. Here, we propose that the ability of NAC to
prevent new depositions of mutant hCC will have a protective
effect on carriers, acting to prevent new strokes from occurring.
While effects on dementia may be minimal, benefits in life
extension could be considerable.
The reduction observed in the cystatin C protein complex
deposition in the skin biopsies of L68Q-hCC carriers with NAC
indicates that NAC can have an effect on hCC aggregation or
deposition in patients when taken orally. As cystatin C deposition
is systemic in HCCAA patients, it is possible that precipitation
and accumulation of amyloid in the brain and blood vessels is
reduced when reduction is observed in the skin. Currently, there
are no noninvasive techniques for observing hCC accumulation
in and around capillaries in the brain, limiting our ability to
directly assess effectiveness. However, apart from what is dis-
cussed below, no new events have occurred in any of the subjects
given NAC, all of whom have continued therapy. The proband is
now approximately over five years post the third and last major
stroke. A minor bleed was observed in the brain of the proband
approximately 12 months ago; however, this bleed surprisingly
spontaneously resolved within 48 h with no clinical effect, which
is very atypical for the natural history of this devastating disease
where recurrent bleeds tend to become more severe. Following on
these observations, a clinical trial has started to evaluate the effect
of NAC therapy on HCCAA patients (EudraCT#: 2017-004776-
56).
We feel there may be a relationship between HCCAA and
other cerebral amyloid angiopathies like Alzheimer’s disease that
is analogous to that of familial combined hypercholesterolemia
(FCH) and general hypercholesterolemia. Statin drugs were
developed to treat familial FCH (patients with FCH develop
stroke and myocardial infarction in their 20 s); it subsequently
became evident that elevated cholesterol was harmful and a major
risk factor for myocardial infarction and stroke, and that patients
with cardiovascular risk factors benefitted from statin treatment.
HCCAA is an enhanced amyloid precipitation that occurs in early
life and leads to catastrophic events in the 20s and early dementia.
This process of protein deposition is somewhat comparable, but
occurs slower in Alzheimer´s disease, leading to dementia much
later in life. If the underlying mechanisms of protein deposition
and pathogenesis are sufficiently similar, similar or identical
treatments may be effective.
In summary, this study provides evidence suggesting that
mutant hCC is a pharmacological target for reducing agents like
NAC, and provides evidence that oral administration of NAC can
affect hCC deposition in the skin of patients with HCCAA. A
larger clinical trial is underway to determine if there is evidence of
other systemic benefits from NAC intake in patients with
HCCAA (EudraCT#: 2017-004776-56).
Methods
Cells and hCC WT vs. L68Q variant expression constructs. Human embryonic
kidney 293 (HEK-239T) cells were obtained from ATCC (Manassas, Virginia) and
grown at 37 °C in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum. A plasmid containing a cDNA of CST3 was obtained
from Dharmacon (Lafayette, CO). The full-length coding sequence was amplified
with a c-terminal Myc tag by PCR and ligated into the EcoRI and NotI sites of
pBABE-CMV-Puro52. The L68Q mutation was introduced by QuikChange site-
directed mutagenesis. Primer sequences are listed in Supplementary Table 1. All
sequences were confirmed by Sanger sequencing. Wild-type and mutant constructs
were transfected into HEK-293T cells using FuGENE HD (Promega, Madison,
WI), with 3 μg of DNA and 9 μl of the transfection reagent, according to the
manufacturer’s protocol. After transfection, cells were incubated with fresh med-
ium containing puromycin (1 µg/ml) for 3 weeks. After selection, stable clones of
each transfectant were generated by limiting dilution. Clones were screened by
Western blot using anti-hCystatin C antibody MAB1196 (R&D,
Minneapolis, MN).
Western blot. HEK-293T cells expressing hCC WT or the L68Q variant were
washed twice with ice-cold phosphate-buffered saline (PBS) and lysed on ice using
a freshly prepared ice-cold cell lysis buffer containing 50 mM Tris-HCl, pH 7.4,
100 mM NaCl, 50 mM β-glycerophosphate, 10% glycerol (w/v), 1% NP-40 (w/v),
1 mM EDTA, 2 mM NaVO4, and a complete, EDTA-free, protein inhibitor cocktail
(Roche Applied Science, Mannheim Germany) at 20 µl per mL of lysis buffer. After
clearing the cell lysates by centrifugation (10 min, 21,000×g, 4 °C), the supernatants
were collected and used for Western blotting. Sample buffer containing SDS,
glycerol, Tris-HCl pH 6.8, and bromophenol blue was added to each sample to the
following final concentrations: 2% SDS, 10% glycerol, 50 mM Tris-HCl, and 0.02%
bromophenol blue. In samples that were reduced, either DTT (50 mM final con-
centration) or β-mercaptoethanol (5% final concentration) were added. Equal
volumes of lysate or supernatant samples were loaded on NuPAGE 4–12% Bis–Tris
gels (Thermo Fisher Scientific, Waltham MA) without heating/boiling. Proteins
were transferred to PVDF membranes (Millipore, Billerica, MA) and blotted with
anti-hCystatin C (MAB1196 [R&D, Minneapolis, MN] used at 500 ng/ml), and
developed by enhanced chemiluminescence (ECL, Thermo Fisher Scientific).
Western blots were acquired via enhanced chemiluminescence using either ECL
film or the KwikQuant Imager from Kindle Biosciences. KwikQuant Images were
processed upon acquisition using manufacturer-provided macros for Adobe Pho-
toshop CC (20161012.r.53 ×64), and densities of bands were determined using the
gel analysis features of Fiji v1.53c53. Graphs and statistical analysis were done in
Graphpad Prism v9.0.0.
Drug treatments. HEK-239T cells were plated on 6-well plates and cultured for
2 days, at which point reduced glutathione (GSH) (Sigma, St. Louis, MO), N-
acetylcystein (NAC) (Sigma), N-acetylcysteine amide (NACA) (Sigma), or N-
acetylcystein-Methyl (NAC-Me) (Sigma) were added to the indicated concentra-
tions. Cells were incubated with indicated compounds for 24 h or 72 h, and 100 μl
samples of supernatants were removed at 24, 48, and 72 h. Supernatants were
cleared by centrifugation (10 min, 21,000×g, 4 °C). Sample buffer containing SDS,
glycerol, Tris-HCl pH 6.8, and bromophenol blue was added to each sample to the
following final concentrations: 2% SDS, 10% glycerol, 50 mM Tris-HCl, and 0.02%
bromophenol blue. When indicated, cells were washed with PBS and lysed and
cystatin C levels were determined by means of Western blot analysis.
Fig. 6 Effects of NAC administration in HCCAA patients. Cystatin C immunostaining (brown stain) was performed on skin biopsies from two separate
cohorts of carriers of the hCC L68Q variant, using a rabbit-anti human cystatin C antibody. a Skin biopsy 1 was obtained when the family participated in
research, approximately 18 months prior to the proband beginning NAC therapy for respiratory issues at this time. Skin biopsy 2 was obtained after
proband had been treated with NAC for 9 months, at which time the parent and sibling began therapy. Skin biopsies 3 were obtained after 6 months of
therapy with NAC (parent/sibling) and 15 months total by the proband. A marked reduction was seen in the proband following the entire course of therapy,
and the parent and sibling after 6 months of NAC therapy. b Skin biopsy 1 was obtained approximately 2 (carrier 1), 1 (carrier 2), or 4 (carrier 3) years ago,
respectively. Skin biopsy 2 was taken following 24 months (carrier 1), and approximately 8 months (carriers 2 and 3) of 600mg of NAC 3× per day.
Numbers in the corner of each image represent the percentage of pixels within the dermis and epidermis that are covered by hCC staining. In a, b, a single-
biopsy section was analyzed per subject per time point. Scale bars are 50mm in all images. c Boxplot represents the quantification by densitometry of the
images before and after the treatment (one-tailed, paired student t test; treated vs. untreated—p= 0.028, number of subjects= 6). The bottom and top
bounds of the box represent the first and third quartiles, respectively, the center line represents the median, and whiskers extend to the extreme-most
points. Data for each subject are represented by the indicated points, and points for subjects before and after treatment are connected by lines.
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Sucrose gradient ultracentrifugation. Lysates of L68Q-hCC untreated or treated
with 10 mM NAC or 5% β-mercaptoethanol were analyzed by sucrose gradient
density ultracentrifugation54. Briefly, cells were lysed in the lysis buffer described
above, and loaded onto a stepwise sucrose gradient composed of 700-μl layers of
sucrose of increasing percentage (top-to-bottom: 5%, 10%, 15%, 20%, 25%, and
30%). Gradients were ultracentrifuged for 16 h at 4 °C at 246,000×g. After cen-
trifugation, fractions were removed from the gradients, 500 μl per fraction. Frac-
tions were numbered 1 (top of gradient, lowest density) through 9 (bottom of
gradient, highest density). Total protein from each fraction was precipitated using
trichloroacetic acid, washed with acetone, and resuspended in 20 μl of PBS. Pro-
teins were prepared for SDS-PAGE under reducing and denaturing conditions, and
L68Q-hCC was detected by western blot.
Statistics and reproducibility. The means and standard deviations of data were
calculated. One-sided t test tests were used to determine the level of significance
with respect to the untreated samples, with p < 0.05 being considered statistically
significant.
For summarization and statistical analysis of western blots, data are derived
from the number of experiments indicated in the figure legend. For Figs. 1, 2, 4,
and 5 the replicate experiments are shown in Supplementary figures, as indicated in
the figure legends. For Supplementary Fig. 1b, the experiment was repeated three
times with similar results.
Tissue samples. All samples were processed at the Department of Pathology,
Landspitali National University Hospital, Reykjavik, Iceland. Punch skin biopsies
(4 mm, central back, one per individual) were obtained. All tissue samples were
formalin-fixed, paraffin-embedded, and cut into 3-μm sections for
immunohistochemistry.
Immunohistochemistry. Sections were deparaffinized and rehydrated in xylene
and ethanol. They were then immunostained using the EnVision Detection System
Peroxidase/DAB, Rabbit/Mouse kit (Dako, K4065). Incubations with primary
antibody (anti-Cystatin C, Sigma, HPA013143, used at 1:100 dilution) were per-
formed at room temperature for 30 min. After incubation with a primary antibody,
sections were incubated with EnVision FLEX/HRP. Sections were washed between
steps with Tris-buffered NaCl solution with Tween 20, pH 7.6 (Dako, S3306). All
sections were incubated with 3,3′-diaminobenzidine solution (Dako, K4065) for
10 min. Sections were counterstained with haematoxylin for 5 min followed by
washing with tap water for 10 min. Finally, sections were dehydrated with 100%
ethanol and xylol followed by coverslipping with mounting medium (Pertex,
Histolab). Images were acquired with a Nikon Eclipse 50i microscope equipped
with a Nikon DS-Fil digital camera and a Nikon Digital Sight DS-U2 camera
controller. Image panels were constructed using the GNU Image Manipulation
Program (GIMP 2.8.10).
Quantification of Cystatin C immunostaining in skin biopsies. Cystatin C
immunostaining in the patient biopsies was quantified by semiautomated image
analysis using the ImageJ software (http://rsbweb.nih.gov/,v1.47). Bright-field
images of a section from all individuals were captured on a Nikon Eclipse 50i
microscope equipped with a Nikon DS-Fil digital camera and a Nikon Digital Sight
DS-U2 camera controller at a resolution of 2560 × 1920 pixels using a Nikon ×4/
0.3NA objective. RGB color images of the sections were imported to ImageJ. On
each image, a rectangular 1300 × 1300-pixel region of interest (ROI) was defined.
The ROI was positioned so that one edge was placed at the periphery of the
epidermis ensuring that the ROI extended over the epidermis and well into the
dermis. The captured RGB image was transformed to the L*, a*, b* color space
(CIE 1976, CIELAB). The b* channel was thresholded using the automated
threshold function of ImageJ and fine-adjusted to correspond to all stained areas on
the section, ensuring a minimal bleed through of differentially stained structures.
Using the thresholded image, the percentage area fraction covered by the threshold
was calculated. The resulting number characterizes the immunostaining load in the
ROI and was subsequently used to quantitatively investigate differences in the
degree of immunostaining between samples22.
Treatment of HCCAA patients with NAC. Three 4-mm skin biopsies were
obtained from the back from each study participants. The first biopsy from the
proband was obtained when she was diagnosed with HCAA prior to initiation of
NAC. The second biopsy was taken after the proband had experienced over
9 months of NAC therapy (400 mg 4× per day) to treat mucus plugging in the
lungs following her third stroke. The third biopsy was taken 6 months thereafter
and during those six months, she was taking 600 mg 3× per day of NAC. Thus, the
proband received 400 mg of NAC 4× per day for 9 months followed by 600 mg of
NAC 3× per day for 6 months. The proband parent and sibling had their first
biopsy taken at the same time as the proband’s first biopsy prior to NAC. Their
second biopsy was taken at the same time the proband had her second biopsy; this
was prior to parent and sibling receiving NAC. The third biopsy was taken
6 months later after the parent and sibling received 600 mg of NAC 3× per day for
6 months.
For the second patient set, two biopsies were taken from each individual. Biopsy
#1 was a historical biopsy performed in 2017 (carrier 1), 2018 (carrier 2), and 2015
(carrier 3), respectively at the time of diagnosis of HCCAA. Biopsy #2 for all three
patients was obtained at the time of enrollment into the NAC clinical trial
(EudraCT#: 2017-004776-56), at which time carrier 1 had taken 600 mg of NAC 3×
per day for over 24 months and carrier 2 for approximately 8 months. Carrier 3
had problem with access to the drug and had taken NAC for less than 8 months at
600 mg 3× per day prior to the second biopsy, including a few stops in between.
Study approval. All necessary permits for the use of skin biopsies from L68Q-
CST3 carriers, and records associated with samples as well as medical information,
were obtained from the National Bioethics Committee of Iceland, reference
numbers 04-046-S2 and 15-060-S1. The study design and conduct complied with
all relevant regulations regarding the use of human study participants and was
conducted in accordance to the criteria set by the Declaration of Helsinki. All
subjects signed the informed consent. The NAC therapy was clinically and ser-
endipitously prescribed as a mucolytic therapy to treat lung atelectasis in the
proband. The other family members and carriers took NAC as a dietary supple-
ment (i.e., purchasing NAC online through Amazon) based on the results from the
cell-based assays, while waiting to formally enroll into a clinical trial that was
designed to assess the efficacy of NAC in patients with HCCAA and launched in
2019. The NAC supplement used by the participants was N-acetylcystein (NAC)
developed by NOW Health Group Inc., IL, USA (available on Amazon).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All uncropped images from western blots are presented in Supplementary Data. Raw data
from patient biopsies in Fig. 6 will be made available upon request to the corresponding
author. We note that HCCAA is a very rare medical condition and only 23 individuals in
Iceland have been diagnosed with the condition. As such, the data are sensitive and will be
deidentified and potentially masked further prior to honoring requests for access to raw data
to protect the identity of the study participants. Source data are provided with this paper.
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